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Abstract
Background and Objectives Previously published studies
have suggested the lack of a pharmacokinetic interaction
between ibuprofen and paracetamol when they are deliv-
ered as a fixed-dose oral combination. The aim of this
study was to determine the pharmacokinetic profile and
safety of a fixed-dose intravenous (IV) combination, con-
taining 3 mg/mL ibuprofen and 10 mg/mL paracetamol, in
comparison with its individual components. The study also
assessed the relative bioavailability of the same doses of
the active ingredients when they were administered as an
oral formulation.
Methods A single-dose, open-label, randomized, five-
period cross-over sequence pharmacokinetic study was
undertaken in 30 healthy volunteers. Serial plasma samples
were assayed for both paracetamol and ibuprofen concen-
trations, using validated liquid chromatography–tandem
mass spectrometry methods. Pharmacokinetic parameters
were computed using standard non-compartmental
analyses. Adverse events were also assessed. The ratios of
the maximum measured plasma concentration (Cmax), the
area under the plasma concentration–time curve (AUC)
from time zero to the time of the last measurable plasma
concentration (AUCt) and AUC from time zero to infinity
(AUC?) were analysed for bioequivalence as determined
by 90 % confidence intervals.
Results The pharmacokinetic parameters of ibuprofen
and paracetamol were very similar for the combination and
monotherapy IV preparations; the ratios of the Cmax, AUCt
and AUC? values fell within the 80–125 % acceptable
bioequivalence range. Precise dose proportionality for both
compounds was also determined for the half dose of the IV
formulation in comparison with the full dose. The relative
bioavailability of paracetamol (93.78 %) and ibuprofen
(96.45 %) confirmed the pharmacokinetic equivalence of
the oral and IV formulations of the fixed-dose combination.
Conclusion Concomitant administration of 3 mg/mL
ibuprofen and 10 mg/mL paracetamol in a fixed-dose IV
combination does not alter the pharmacokinetic profiles of
either drug. The IV and oral dose forms of such a combi-
nation are pharmacokinetically equivalent.
Key Points
Concomitant administration of 3 mg/mL ibuprofen
and 10 mg/mL paracetamol in a fixed-dose
intravenous combination does not alter the
pharmacokinetic profile of either drug.
The intravenous and oral dose forms of such a
combination are pharmacokinetically equivalent.
This study was registered on the Australian New Zealand Clinical
Trials Registry (trial ID: ACTRN12614000809639).
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1 Introduction
Ibuprofen and paracetamol are among the most commonly
used analgesics and are widely available without a pre-
scription [1]. Ibuprofen is a non-steroidal anti-inflamma-
tory drug (NSAID), which non-selectively inhibits
cyclooxygenase isozymes 1 and 2 (COX-1 and COX-2),
resulting in inhibition of prostaglandins and related com-
pounds at peripheral sites [2]. Contrastingly, the mode of
action of paracetamol is not fully understood but is thought
to relate to inhibition of either prostaglandin synthesis or
cannabinoid receptors [3].
A fixed-dose combination of ibuprofen
300 mg ? paracetamol 1000 mg (FDC 300/1000), when
formulated as oral tablets (henceforth referred to as ‘FDC-
oral’), has been shown to provide superior pain relief in
comparison with its individual components [4]. An intra-
venous (IV) formulation of FDC 300/1000 (henceforth
referred to as ‘FDC-IV’) has been developed to permit its
administration to patients in whom the use of oral anal-
gesics is limited by various patient factors, such as inability
to swallow, the presence of postoperative nausea and
vomiting, or reduced gastric motility.
Previous studies have demonstrated that oral ibuprofen
and paracetamol are rapidly absorbed after oral adminis-
tration and are not subject to significant first-pass metabo-
lism [5–9], and that concomitant administration of both
compounds does not result in a pharmacokinetic interaction
[10–12]. In comparison with oral dosing, the same doses of
ibuprofen and paracetamol administered in an IV formula-
tion result in twofold and 70 % increases in the maximum
measured plasma concentration (Cmax) values, respectively
[5, 13]. Furthermore, IV ibuprofen demonstrates great dose
proportionality with respect to the area under the plasma
concentration–time curve (AUC) and Cmax [6, 14].
The results of this study, which was conducted with
aims to (1) describe the pharmacokinetic profile of the IV
formulation of FDC-IV; (2) confirm the lack of a phar-
macokinetic interaction between ibuprofen and paraceta-
mol following IV administration; (3) determine whether
dose proportionality is apparent from comparison of the
full-dose combination of FDC-IV and the half-dose com-
bination; and (4) establish the relative bioavailability of
FDC-oral versus that of FDC-IV, are reported here.
2 Methods
2.1 Trial Design
This study was a phase I, single-centre, single-dose, open-
label, randomized, five-way cross-over trial in 30 healthy
adult participants. After an initial screening period of up to
28 days, there were five study periods, separated by
washout periods of at least 48 h, and a subsequent final
follow-up period of up to 7 days. The research was con-
ducted in accordance with Good Clinical Practice (GCP),
including the Declaration of Helsinki and all applicable
regulatory requirements. The study protocol received
approval by the Health and Disability Ethics Committee,
Ministry of Health, New Zealand, and the trial was regis-
tered with the Australian New Zealand Clinical Trial
Registry (trial ID: ACTRN12614000809639).
2.2 Study Population
Healthy volunteers of both genders, 18–50 years of age
with a body mass index (BMI) of 18.0–32.0 kg/m2, were
recruited from the Christchurch Clinical Studies Trust
databases. Informed consent was obtained by the principal
investigator from all individual participants included in the
study prior to the screening visit. Screening involved a
physical examination and recording of demographic data,
vital signs, the medical history and concomitant medica-
tions. A blood sample was taken for haematology, bio-
chemistry and serology screening, and a urine sample was
collected for urinalysis, and illicit-drug and alcohol breath
screening tests were performed. Suitable participants had to
comply with all study inclusion and exclusion criteria
(presented in Table 1).
2.3 Treatment and Study Procedures
Participants were randomized in a cross-over fashion to a
study sequence of four IV doses and one oral dose, using a
computer-generated list prior to commencement. For all
doses, participants were confined to the study centre from
the previous evening to approximately 12 h after study
drug administration. The study drug was administered in
the morning, following a 10-h fast, and a standard lunch
and snacks were provided at 4 and 8 h after study drug
administration, respectively.
Patients received each of the following five treatments in
a randomized order:
• Treatment A (FDC-IV: 3 mg/mL ibuprofen ? 10 mg/
mL paracetamol, 100 mL IV)
• Treatment B (10 mg/mL paracetamol, 100 mL IV)
• Treatment C (3 mg/mL ibuprofen, 100 mL IV)
• Treatment D (FDC-IV half dose: 1.5 mg/mL ibupro-
fen ? 5 mg/mL paracetamol, 100 mL IV)
• Treatment E (FDC-oral: ibuprofen 150 mg ? paraceta-
mol 500 mg per tablet, 2 tablets)
Treatments A, B, C and D were manufactured by
SM Farmaceutici SRL, Italy, and administered as a slow
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IV infusion over 15 min into an indwelling cannula.
Treatment E was manufactured by Sigma Laboratories,
India, and administered orally with 240 mL of water.
2.4 Sampling Schedule
Blood samples (approximately 5 mL) for pharmacokinetic
analysis were collected into lithium–heparin tubes. The
blood sampling schedules were different for the IV and
tablet formulations, as outlined below:
Sampling time points for the intravenous formulations
Blood samples were drawn pre-dose, on completion of
the 15-min IV infusion, at 5, 10, 15, 20, 30 and 45 min,
and at 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10 and 12 h post-
completion of the infusion.
Sampling time points for the tablet formulation Blood
samples were drawn pre-dose, at 5, 10, 20, 30 and
45 min, and at 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10 and 12 h after
study drug administration.
2.5 Bioanalytical Methods
All haematology, biochemistry and urinary analyses were
conducted using standard methodologies within a single
laboratory. Plasma concentrations of paracetamol and
ibuprofen in human plasma (lithium–heparin) were deter-
mined using validated liquid chromatography–tandem
mass spectrometry (LC–MS/MS) procedures.
Paracetamol plasma concentrations were analysed using
API 3000 and Quattro premier mass spectrometry in mul-
tiple reaction monitoring (MRM) mode, using a turbo ion
spray with positive ionization. The chromatographic sep-
aration of paracetamol employed a C18 column, using a
mobile phase consisting of de-ionized water, formic acid
and acetonitrile. The calibration curves were linear over the
working range of 50–20,000 ng/mL, with a regression
coefficient (R2) of C0.99937. The lower limit of quantifi-
cation (LLOQ) was 50 ng/mL (precision 3.44 %, accuracy
93.69 %).
Ibuprofen plasma concentrations were analysed using a
Sciex API 3000 and API 4000 triple quadrupole mass
spectrometer in MRM mode, using a turbo ion spray with
negative ionization. Selective analysis of ibuprofen was
achieved on a Symmetry C18 column by using a mobile
phase consisting of ammonium formate, methanol and
acetonitrile. The calibration curves were linear over the
concentration range of 50–35,000 ng/mL, with an R2 of
C0.9975. The LLOQ was 50 ng/mL (precision 8.85 %,
accuracy 104.25 %). These methods have also been
described elsewhere [10].
2.6 Pharmacokinetic Analysis
The pharmacokinetic parameters of paracetamol and
ibuprofen were calculated using Excel 2013. Cmax and the
time to reach Cmax (Tmax) were determined directly from
the raw data. The elimination rate constant (ke) was cal-
culated from the slope of the linear relationship between
the loge concentration and the time during the terminal
elimination phase. AUC from time zero to the time of the
last measurable plasma concentration (AUCt) was calcu-
lated by the linear trapezoidal rule, and AUC from time
zero to infinity (AUC?) was calculated after extrapolation
from time t to infinity as the ratio of the last measurable
plasma concentration (Clast) to ke. The elimination half-life
(t) was estimated from the elimination rate constant as
ln(2)/ke.
Table 1 Study inclusion/exclusion criteria
Inclusion criteria
Male and female volunteers aged 18–50 years (inclusive) on the day of consent
Voluntary provision of written informed consent before initiation of any study-related procedures
Body mass index of 18.0–32.0 kg/m2
No significant disease (cardiac, pulmonary, gastrointestinal, hepatic, renal, haematological, neurological, infective or psychiatric) according
to the medical history, physical examination and laboratory tests, as determined by the principal investigator
Exclusion criteria
Pregnant or nursing women
Women of childbearing potential who were unwilling to take adequate contraceptive precautions or who were unwilling to undergo a urine
pregnancy test
Alcohol intake[14 units/week for females and[21 units/week for males
History of drug abuse or positive test results for drug abuse
Use of prescription drugs (not including oral contraceptives) within 14 days prior to study drug administration; or use of over-the-counter
drugs, herbal products or vitamins within 7 days prior to study drug administration, unless the principal investigator and sponsor agreed that
the product that was taken would not have an impact on the study conduct, study results or participant safety
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2.7 Statistical Methods
Statistical analysis was performed using the validated pro-
gramSPSS v22.0. The ratios used to test bioequivalencewere
calculated from loge-transformed data for Cmax, AUCt and
AUC?. The differences between the logemeans and the 90 %
confidence intervals (CIs) of the differences, derived from the
residual variance from the analysis of variance (ANOVA)
model, were back-transformed to estimate the ratios of the
two formulations and the 90 % CIs of these ratios.
2.8 Safety
Safety was assessed in terms of the overall proportion of
subjects with adverse events (AEs) and by haematological
and biochemical assessment of blood samples. AEs were
evaluated for their severity (mild, moderate or severe)
according to the subjective impact they had on the per-
formance of daily activities and their likely relationship to
the medication (not related, unlikely, possibly, probably or
definitely related) according to the likelihood of a temporal
association between the onset of the event and the
administration of the medicinal product.
3 Results
3.1 Participants
Thirty subjects were enrolled in this study; 23 (77 %) were
male, and all were Caucasian. The mean (± standard devi-
ation) age and BMI were 29.9 (±19.4) years and 24.5
(±2.9) kg/m2, respectively. Twenty-nine participants com-
pleted the study, each of whom received all five treatments
and was included in the pharmacokinetic analysis.
3.2 Pharmacokinetic Results
Themean paracetamol plasma concentration–time curves for
ibuprofen and paracetamol are presented in Figs. 1 and 2,
respectively. A tabulated summary of the pharmacokinetic
data for both compounds is also presented in Table 2.
Intravenous infusions resulted in mean Cmax values of
26,709.6 ng/mL (FDC-IV) and 26,236 ng/mL (paraceta-
mol IV) immediately after the 15-min infusion. A half dose
of FDC-IV provided a mean Cmax of 12,880 ng/mL. The
concentration of paracetamol from the FDC-oral tablets
peaked at 0.73 h, with a mean Cmax of 14,907 ng/mL. The
oral route provided paracetamol Cmax values 44 % lower
than those observed after administration of FDC-IV or
paracetamol IV.
Similarly, IV infusions resulted in Cmax values of
39,506.7 ng/mL (FDC-IV) and 40,292.97 ng/mL
(ibuprofen IV) immediately after the 15-min infusion. A
half dose of FDC-IV provided a mean Cmax of 20,352 ng/
mL. The concentration of ibuprofen from the FDC-oral
tablets peaked at 1.49 h, with a mean Cmax of 19,637 ng/
mL. The oral route provided ibuprofen Cmax values 50 %
lower than those observed after administration of FDC-IV
or ibuprofen IV.
The corresponding AUCt and AUC? values were very
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Fig. 1 Mean (standard error of the mean) paracetamol plasma
concentrations after single administration of FDC-IV (treatment A:
3 mg/mL ibuprofen ? 10 mg/mL paracetamol, 100 mL IV), parac-
etamol IV (treatment B: 10 mg/mL paracetamol, 100 mL IV), FDC-
IV half dose (treatment D: 1.5 mg/mL ibuprofen ? 5 mg/mL parac-
etamol, 100 mL IV) and FDC-oral (treatment E: ibuprofen
































Time, hr (since the start of infusion/administration of tablets)
FDC-IV Half dose
FDC-Oral Tablets
Fig. 2 Mean (standard error of the mean) ibuprofen plasma concen-
trations after single administration of FDC-IV (treatment A: 3 mg/mL
ibuprofen ? 10 mg/mL paracetamol, 100 mL IV), ibuprofen IV
(treatment C: 3 mg/mL ibuprofen, 100 mL IV), FDC-IV half dose
(treatment D: 1.5 mg/mL ibuprofen ? 5 mg/mL paracetamol,
100 mL IV) and FDC-oral (treatment E: ibuprofen 300 mg ? parac-
etamol 1000 mg, 2 tablets). FDC fixed-dose combination,
IV intravenous
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FDC-oral tablets. The back-transformed 90 % CIs for
FDC-IV in comparison with paracetamol IV and ibuprofen
IV all fell within the 80–125 % acceptable bioequivalence
range, thus confirming the lack of any pharmacokinetic
interaction when both paracetamol and ibuprofen are given
in combination as a parenteral preparation (Table 3).
Comparisons of the Cmax, AUCt and AUC? values for
FDC-IV and a half dose of FDC-IV demonstrated consis-
tent dose proportionality for both paracetamol and
ibuprofen (Table 4). The t values for paracetamol and
ibuprofen were found to be comparable between all treat-
ment groups (Table 2).
The relative bioavailability of paracetamol and ibupro-
fen from the FDC-oral tablets was calculated from the
back-transformed ratios of the loge means of the AUC?
values for the oral and IV formulations (AUCFDC-oral/
AUCFDC-IV). For FDC-oral, the relative bioavailability of
paracetamol was 93.78 % (90 % CI 90.98–96.67 %) and
the absolute bioavailability of ibuprofen was 96.45 %
(90 % CI 93.13–99.89 %), suggesting nearly complete
absorption of both compounds from the gastrointestinal
mucosa. These results are summarized in Table 5.
3.3 Safety Analysis
Twenty-five non-serious AEs were reported by 15 subjects
(50 %). The majority of AEs were mild (80 %), and all
other AEs were moderate (20 %). There were no severe
AEs. Seventy-six percent of AEs were not related to the
study medication in that a temporal association between the
onsets of the events relative to the administration of the
product was not reasonable. Twenty-four percent of AEs
had a reasonable temporal relationship between their onset
and administration of the study medication, and were
deemed either ‘unlikely related’ or ‘possibly related’ on the
basis of the subjective likelihood of the association. These
data, and the distribution of AEs across the study periods
(study drug or washout), are presented in Table 6. One
subject did suffer a serious AE: bilateral ankle fractures
due to a fall.
Table 2 Mean ± standard deviation pharmacokinetic parameters of paracetamol and ibuprofen from each treatment
Paracetamol Treatment (mean ± standard deviation)
FDC-IV: treatment A Paracetamol IV: treatment B FDC-IV half dose: treatment D FDC-oral: treatment E
Cmax (ng/mL) 26,709.57 ± 5814.74 26,236.06 ± 5430.52 12,880.39 ± 2553.15 14,907.16 ± 6255.10
AUCt (ngh/mL) 37,553.97 ± 9816.96 35,846.20 ± 8734.15 18,327.40 ± 4758.34 34,980.80 ± 9430.21
AUC? (ngh/mL) 39,419.95 ± 10,630.63 37,651.43 ± 9454.60 19,337.01 ± 5146.46 37,023.82 ± 10,388.31
Tmax (h)
a 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.02 0.73 ± 0.42
t (h) 2.39 ± 0.27 2.38 ± 0.25 2.44 ± 0.25 2.51 ± 0.33
Ibuprofen Treatment (mean ± standard deviation)
FDC-IV: treatment A Ibuprofen IV: treatment C FDC-IV half dose: treatment D FDC-oral: treatment E
Cmax (ng/mL) 39,506.69 ± 6874.06 40,292.97 ± 7460.04 20,352.05 ± 3090.87 19,637.38 ± 5178.29
AUCt (ngh/mL) 73,492.69 ± 16,509.61 72,169.59 ± 15,608.70 39,642.48 ± 9679.16 70,417.75 ± 16,260.16
AUC? (ngh/mL) 74,743.31 ± 17,388.69 73,410 ± 16,500.76 40,333.88 ± 10,240.30 72,202.48 ± 17,445.46
Tmax (h)
a 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 1.49 ± 0.89
t (h) 1.87 ± 0.27 1.88 ± 0.28 1.88 ± 0.30 1.99 ± 0.36
AUCt from time zero to the time of the last measurable plasma concentration, AUC? area under the plasma concentration–time curve from time
zero to infinity, Cmax maximum measured plasma concentration, t half-life, Tmax time to reach Cmax
a Hours after the end of administration
Table 3 Bioequivalence comparison of FDC-IV (treatment A) and standalone IV preparations of paracetamol (treatment B) and ibuprofen
(treatment C) Cmax, AUCt and AUC? [point estimate % (90 % CI) from log-transformed data]
Paracetamol: treatment A/B Ibuprofen: treatment A/C
Cmax (ng/mL) 101.67 (95.97–107.72)
a 98.30 (93.82–102.99)a
AUCt (ngh/mL) 104.24 (101.42–107.13)a 101.57 (98.35–104.89)a
AUC? (ngh/mL) 104.15 (101.13–107.26)a 101.55 (93.82–105.00)a
AUCt from time zero to the time of the last measurable plasma concentration, AUC? area under the plasma concentration–time curve from time
zero to infinity, CI confidence interval, Cmax maximum measured plasma concentration, FDC fixed-dose combination, IV intravenous
a Within the bioequivalence range
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4 Discussion
For oral medications, increased absorption time and first-
pass metabolism, or inconsistent absorption in hospitalized
patients, due to delayed gastric emptying perioperatively,
may result in a latency to or lack of clinical effect [15].
Indeed, in a study of 106 patients undergoing ear, nose and
throat surgery, plasma concentrations of paracetamol
1000 mg sufficient to provide an analgesic effect (10 mg/L)
were reached in 96 % of patients who received the drug
parenterally and in only 67 % patients who received it orally
[16]. FDC-IV has been developed for use in instances where
oral therapy is limited by sedation, severe illness or debili-
tation, or in patients with difficulty in swallowing.
4.1 Interaction
The results of this study demonstrate that concurrent
administration of ibuprofen and paracetamol in a novel IV
fixed-dose combination did not significantly alter the extent
of absorption of ibuprofen or paracetamol, in comparison
with either agent alone. A lack of a pharmacokinetic inter-
action between ibuprofen and paracetamol has been docu-
mented for the following oral formulation, fixed-dose
combinations: ibuprofen 300 mg ? paracetamol 1000 mg
[10], ibuprofen 400 mg ? paracetamol 1000 mg [11] and
ibuprofen 400 mg ? paracetamol 650 mg [12]. In these
products, after oral administration, the values of the phar-
macokinetic parameters Cmax, AUCt and AUC? for both
ibuprofen and paracetamol were similar with the fixed-dose
combinations and monotherapies, and the back-transformed
90 % CI for each parameter fell within the acceptable
bioequivalence range (80–125 %) [10, 11]. Similar results
were obtained from comparison of pharmacokinetic
parameters by ANOVA for the third fixed-dose combination
[12]. Consequently, the results from the present study con-
firm and extend such results for an IV formulation.
4.2 Dose Proportionality
The dose proportionality of the FDC-IV formulation pro-
vided here is consistent with that reported for IV ibuprofen;
a twofold lesser dose results in decreases of 44–51 % in
Cmax, AUCt and AUC? [6, 14]. Absorption of paracetamol
from a half dose of FDC-IV appeared to be slightly
delayed; however, the longer mean Tmax in this group was
due to a single patient whose paracetamol Cmax occurred
20 min after the start of the 15-min infusion (5 min after
the end of the infusion). The clearance of both compounds
remained constant (2.4 h for paracetamol and 1.8 h for
ibuprofen), which is consistent with previous findings for
ibuprofen [6]. The clear dose proportionality of absorption
of both active ingredients in FDC-IV could provide prac-
titioners with the ability to easily titrate analgesia accord-
ing to their patient’s pain.
4.3 Relative Bioavailability
This study determined that both active ingredients in the
FDC-oral formulation have very high bioavailability. In
comparison with FDC-IV, the relative bioavailability val-
ues for ibuprofen and paracetamol in the FDC-oral tablets
Table 4 Dose proportionality of FDC-IV, expressed as a comparison between FDC-IV (treatment A) and FDC-IV half dose (treatment D) for
paracetamol and ibuprofen Cmax, AUCt and AUC? [point estimate % (90 % CI) from log-transformed data]
Paracetamol: treatment A/D Ibuprofen: treatment A/D
Cmax (ng/mL) 206.89 (196.27–218.08) 193.49 (185.70–201.61)
AUCt (ngh/mL) 204.49 (199.31–209.79) 185.84 (181.10–190.71)
AUC? (ngh/mL) 203.89 (198.37–208.58) 185.81 (180.90–190.87)
AUCt from time zero to the time of the last measurable plasma concentration, AUC? area under the plasma concentration–time curve from time
zero to infinity, CI confidence interval, Cmax maximum measured plasma concentration, FDC fixed-dose combination, IV intravenous
Table 5 Relative bioavailability of FDC-oral determined by ratios of FDC-oral and FDC-IV geometric means of ibuprofen and paracetamol
AUC? values [point estimate % (90 % CI) from log-transformed data]
FDC-oral: treatment Ea FDC-IV: treatment Aa Relative bioavailability: treatment E/A
Paracetamol AUC? (ngh/mL) 35,721.16 38,091.23 93.78 (90.98–96.67)b
Ibuprofen AUC? (ngh/mL) 70,233.598 72,814.966 96.45 (93.13–99.89)b
AUC? area under the plasma concentration–time from time zero to infinity, CI confidence interval, FDC fixed-dose combination,
IV intravenous
a Geometric mean
b Within the bioequivalence range
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are 93.59 and 96.34 % respectively, confirming the asser-
tion that both compounds are not subject to significant pre-
systemic metabolism. These results are congruent with
previously published data [5–9].
Absorption via the gastrointestinal mucosa results in
delayed absorption and decreased Cmax values. In com-
parison with FDC-IV, the Cmax values for ibuprofen and
paracetamol were reduced by 50 and 44 %, respectively,
after administration of FDC-oral. For ibuprofen, the results
of this study are in line with other published data; an
equivalent oral dose of ibuprofen results in a Cmax value
that is 50 % of the value observed after an IV dose (63
versus 120 lg/mL) [5]. For paracetamol, oral dosing has
been shown to reduce Cmax of paracetamol 1000 mg by
41–43 % in healthy volunteers [9, 13].
5 Conclusion
This study confirmed that a combination of 3 mg/mL
ibuprofen and 10 mg/mL paracetamol (FDC-IV) produces
ibuprofen and paracetamol plasma concentration–time
Table 6 Distribution of adverse events by study period/treatment, severity and relationship with medication
Treatment period and adverse event Grading of adverse events
Severitya Relationship to study medicationb
FDC-IV
Right superficial radial nerve irritation secondary to cannulation on right wrist Mild Not related
Bruised cannulation site on left forearm Mild Not related
Upper respiratory tract infection Mild Not related
Nausea Mild Possibly related
Paracetamol IV
Upper respiratory tract infection Mild Not related
Lethargy Mild Possibly related
Vasovagal episode Moderate Not related
Headache Moderate Not related
Dyspepsia Moderate Possibly related
Ibuprofen IV
Upper respiratory tract infection Mild Not related
Rectal bleeding Mild Unlikely related
Diarrhoea Moderate Unlikely related
FDC-IV half dose
Sore throat Mild Not related
FDC-oral
Vasovagal episode Mild Not related
Bruising at cannula site on left forearm Mild Not related
Presyncopal episode Moderate Not related
Washout
Upper respiratory tract infection Mild Not related
Dry cough Mild Not related
Nasal congestion Mild Not related
Headache Mild Not related
Headache Mild Not related
Upper respiratory tract infection Mild Not related
Bruising at cannula site on right forearm Mild Not related
Bruising at failed cannula site on right wrist Mild Not related
Rectal bleeding Mild Unlikely related
FDC fixed-dose combination, IV intravenous
a Mild: discomfort noticed but no disruption of normal daily activity; moderate: discomfort sufficient to reduce or affect daily activity
b Unlikely related: a temporal (timely) relationship of the onset of the event, relative to the administration of the product, is unlikely but cannot
be ruled out; possibly related: a temporal (timely) relationship of the onset of the event, relative to the administration of the product, is
reasonable, but the event could have been due to an equally likely cause
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profiles that are similar to those observed after IV admin-
istration of each component on its own. The pharmacoki-
netic profile of the IV formulation has been demonstrated
to be dose proportional following administration of single
doses of 1.5 mg/mL ibuprofen and 5 mg/mL paracetamol
(FDC-IV half dose) and 3 mg/mL ibuprofen and 10 mg/
mL paracetamol (FDC-IV).
The pharmacokinetic parameters were observed to be
similar when a single dose of FDC 300/1000 was adminis-
tered in either an IV formulation (FDC-IV) or an oral for-
mulation (FDC-oral), except for Cmax of the IV formulation,
which was twice that of the oral formulation, and, as
expected, Tmax was much shorter than with the oral dose.
The relative bioavailability of paracetamol (93.78 %) and
ibuprofen (96.45 %) confirmed the pharmacokinetic
equivalence of the oral and IV FDC 300/1000 formulations.
Consequently, in instances where delayed gastric emp-
tying is expected, an IV formulation of FDC 300/1000 may
provide more efficient analgesic delivery.
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